Displaying 87 (all) recruiting clinical trials.
-
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
This study will focus on improving chemotherapy response rates in both primary and metastatic rectal and colorectal cancer. In this study, patients will be divided ...
-
A single arm phase II study of ADjuvant Endocrine therapy subcutaneous Pertuzumab and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive HER2-positive breast cancer (ADEPT)
You can participate in this study if you are diagnosed with stage I, hormone receptor-positive (HR+) and human epidermal growth factor receptor-2.positive (HER2+) breast ...
-
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors
This study wants to see if a new medicine called futibatinib, when used with pembrolizumab (a type of treatment that helps the immune system fight ...
-
A Phase II Open-Label Multicenter Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
This is a study testing two different treatments for patients with pancreatic cancer after surgery. The study team want to see if adding two drugs ...
-
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination with Ipilimumab Nivolumab and Relatlimab in Patients with Unresectable Stage III or Stage IV Melanoma
This study is looking at a treatment for advanced melanoma, a type of skin cancer. The study has two parts. First, patients will get a ...
-
A Phase 2b Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
The purpose of this study is to learn about the safety and effectiveness of a new experimental drug called MORF-057, in people with moderately to ... -
A Phase 2 Open-Label Multi-Center Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible fo
This study looks at two treatments (TAR-200 + IV cetrelimab versus IV cetrelimab alone) for a specific kind of bladder cancer (muscle-invasive bladder cancer unsuitable for ...